The Ph.D. Programme in Molecular and Experimental Medicine (MEM) aims to address some of the main challenges of life sciences in a highly competitive scientific research environment
The MEM PhD Programme provides training in various fields of life sciences and molecular medicine offering a stimulating environment with access to state-of-the-art technology and clinical case lists for translational studies.
Two different curricula are available: candidates are required to specify their curriculum preferences when applying.
The MEM Curriculum provides for the research activities to develop along, yet not remain limited to, the following main areas, including: oncological immunopathology, molecular cardiometabolics, genetics, neurosciences. An overall vision of regenerative and precision medicine is the theme running throughout the programme. The curriculum provides specific training for enabling technologies, such as imaging, flow cytometry, genomics and bioinformatics.
The MEM-Clinical curriculum aims to combine basic or clinical experimental research activities with clinical practice involving patient enrolment and assessment in specific trials. The course provides for ordinary clinical practice in the hospital under the supervision of a doctor (up to a maximum of 20 hours per week) and experimental laboratory activities, which include but are not limited to cellular and molecular biology, information technology, immunology and the use of preclinical models. Candidates will be directly responsible for research projects approved by their clinical supervisor and/or laboratory head.
For both curricula the PhD will be conducted in a stimulating environment involving the organisation of Journal clubs and seminars given by national and international speakers, participation in congresses, informal meetings between different disciplines, encouraging researchers to work independently and collaboration with groups abroad. Liaising with tutors and non-Italian discussants further develops the international dimension.
|PhD Coordinator: Prof Maria Rescigno|
|Beginning of the academic year
1st January 2021
Career Opportunities for Humanitas PhD students
The PhD program aims to train experts in clinical and industrial research, preparing them to take up careers in biotech companies, in translational research, in clinical or academic fields worldwide. Thanks to a “translational” approach, professionals will quickly transfer new knowledge from basic sciences to bio-medicine with the aim of creating new and advanced diagnostic and therapeutic applications.
The PhD course in Molecular and Experimental is articulated into three main types of didactic activities:
Every student is assigned a research topic under the supervision of a Supervisor; the research activity in the laboratory is a full-time activity
Mandatory frontal activities
Linguistics, Informatics, Research management and funding, Intellectual property are the main topics
2.1 Mandatory courses (*) – minimum 1 day
2.2 Seminar series (Journal Club on a specific topic between the speaker and the PhD students followed by a public seminar on the same topic)
Seminars and courses, offered by the Humanitas University and Humanitas Research Labs, which the PhD students can freely join according to their research field and interests.
Mandatory Courses (*)
|Scientific Methods||I||Rosella Visintin||1,5|
|Scientific Writing||II||Miriam Alcalay||1,5|
Applicants wishing to enrol on the PhD course in Molecular and Experimental Medicine, MEM Curriculum must either have a “laurea magistrale” awarded in accordance with D.M. 270/2004 or equivalent qualification awarded by a foreign university (usually referred to as a Master’s Degree), in one of the subjects listed in the official call for applicants.
Applicants who are waiting to be awarded the required qualification at the date of submission can also take part in the selection process providing they have passed all of the Degree course exams at the time of the online application and are awarded the qualification before the beginning of the academic activities. In the event these applicants pass the selection process, their enrolment on the PhD course is conditional upon providing proof that the qualification is awarded.
Applicants wishing to enrol on the PhD Course in Molecular and Experimental Medicine, MEM-Clinical Curriculum must:
- be enrolled on the Medical Register
- already possess a specialist medical qualification
Alternatively, applications will also be taken from doctors in specialist training who will enrol in the final year in a School of Specialisation at Humanitas University
Doctors in specialist training who are already enrolled in the final year of Specialisation at any university and who will complete their training by October 31st 2020. In the event these applicants pass the selection process, they may conditionally enrol on the PhD Course and are required to provide proof of the awarded qualification by the beginning of academic activities.
Scholarships and fees
PhD students are required to pay an annual fee for access and attendance, set at € 250,00 for the academic year 2020/2021, including the regional tax and stamp duty.
Associazione Alan Ghitis and Humanitas University
Humanitas University is an international hub for the training of doctors and researchers capable of dealing with future scientific, technological and social change. The close integration between the Hospital, the Research Laboratories and the University creates the conditions for healthcare professionals to gain experience by working closely with patients and at the same time acquire the methodology and rigour that scientific research requires – a means to creating synergy between clinical and laboratory practice in an educational context. The bibliometric indexes demonstrate the outstanding quality and quantity of scientific research at Humanitas, proliferating year after year. The Impact Factor places Humanitas in one of the top positions for its scientific production, particularly in the field of the immune system, a must for today’s medical research, given its high impact on wideranging clinical practice.
The immune system
The immune system plays a major role in controlling tumor development via a process which is called immune surveillance. When a cell becomes neoplastic, the immune system recognizes its cancerous state and kills it. Tumor cells display a sort of a flag on their surface to alert the immune system to be eliminated (Figure 1). Unfortunately, when tumor cells find strategies to evade the immune system, they start growing undisturbed. They can either avoid displaying the flag (they hide themselves) or can inactivate immune cells capable of recognizing the flag (Figure 1). Recent advancement in cancer therapy has demonstrated that strategies aimed at reactivating the immune response are very powerful. They can reactivate the immune cells that recognize the flag. Belong to this type of immunotherapy the so called immune check point inhibitors whose discovery earned a Nobel prize to the inventors in 2018 (Figure 2a). These immune checkpoint inhibitors, however, are ineffective when there are no immune cells to recognize the flag to be reactivated. In this case another strategy aimed to instruct immune cells to recognize de novo the flag has been proposed. This strategy resembles the vaccination against infectious agents, with the difference that the enemy to attack in this vaccination is the tumor (Figure 2b). It is not preventive but should be administered to patients already having a tumor either just after its removal to avoid recurrence of the disease, or in patients with metastases where surgical removal is not feasible. While immune checkpoint inhibitors have demonstrated to be very powerful, vaccination is still under evaluation, and probably the combination with immune checkpoint blockade can improve its efficacy. We have proposed a new strategy of vaccination that has been financed by the Italian foundation for cancer research (AIRC 5×1000) and that we will be testing in a clinical trial on metastatic melanoma patients.
In some patients vaccination coupled to immune checkpoint inhibition may still not be successful because of the ability of tumor cells to avoid displaying the flag. With the Alan Ghitis fellowship, a PhD student at Humanitas University and Research hospital will evaluate strategies to induce the tumor cell to express the flag on their cell surface so to avoid hiding from the immune system (Figure 2c).
Cancer immunotherapy and the advent of immune checkpoint blockade has revolutionized cancer treatment. It reactivates the immune system to recognize and kill tumor cells. Although a good proportion of patients respond to immune checkpoint blockade, still many do not. This is because they do not have an immune response to be reactivated. Within the AIRC 5×1000 project, which funds a network of 8 units in 4 different institutions in Italy, we will vaccinate patients so to improve immunocheckpoint based intervention. With the Alan Ghitis fellowship, a PhD student at Humanitas University and Research hospital will further this approach by evaluating strategies to induce the tumor cell to re-express a flag on their cell surface that alerts the immune system of their neoplastic nature to allow immune cells to recognize it and kill it.
What is the Associazione Alan Ghitis?
Associazione Alan Ghitis was founded in February 2019 by the family and friends of Alan Ghitis, who valiantly fought but lost at the age of 40 the battle against melanoma skin cancer.
The Founders wish to continue his fight so that others may have a better chance. The purpose of the Association is to engage in the fight against cancer by promoting oncological research and supporting cancer patients and their families. Melanomas will be given precedence, but all form of cancers will be considered.
The Association may engage in oncological research by contributing to projects by private, public or university organizations. It may also distribute scholarships to university students in cancer research, as well as finance especially innovative start-up projects in cancer research by entities or individuals. It may also want to contribute to hospitals and/or clinics in their purchase of equipment destined to cancer therapy.
Experience of a student who received the Alan Ghitis Scholarship
Valentina Ferrari, Alan Ghitis Scholarship winner, answers the following questions.
What does the Alan Githis fellowship mean to you?
The Alan Ghitis scholarship is special to me because it has given me the amazing opportunity to learn cutting edge technology from top scientists in the field of cancer research.
Why did you choose to work on cancer?
I am passionate about this disease because, for me, cancer is personal – after my mom was diagnosed with ovarian cancer, I became adamant in my pursuit of knowledge in the field of cancer immunotherapy and continue to be so today.
How to Apply
- Registration or access with your LOGINMIUR credentials
- Application form submission
- Payment of the application contribution
The application form must be completed in all its parts, on penalty of exclusion. In particular, applicants must submit all of the following documents in PDF format:
- Curriculum vitae
- Motivation letter
- Copy of a valid ID or passport (for Non-EU citizens)
- Diploma Supplement
- Copy of the receipt of payment of € 30,00
Additionally, applicants may indicate name and contacts of maximum two referees, preferably chosen among those who have had a supervising role of the candidates. The referees will be directly contacted by Humanitas University and asked to complete a brief letter of reference.
Further details about the application procedure will be reported in the official call for applicants.
Admission to the PhD Programme is based on a public selection process consisting of
- the comparative evaluation of the titles and qualifications and
- an interview carried out in English by a Committee composed of a maximum of seven members.
The aim of the selection process is to assess the knowledge, competencies and aptitude of the applicants for scientific research as well as their motivation for undertaking the PhD programme.
Prior to the interview, applicants may be asked to take a multiple choice test, aimed at assessing the applicant’s specific knowledge in the fields of the research projects of the Campus.
A good knowledge of English is required and will be tested during the interview.
Should reasons justify it, the test and interview can be conducted via video-conference. Those who intend to conduct the interview via video-conference or request special assistance should specify this on the application form.
The first ranking list with short list for oral interviews will be publish starting from October 31st 2020.
The Final ranking list will be posted on this page in the week starting on October 31st 2020.
2020-2021 available positions and topics
There are 8 positions available.
Additional places and/or scholarships may become available based on external fundings.
The number of available places and/or scholarships may increase in the event that external funding for additional places or scholarships becomes available by the deadline set for the completion of the call application procedure.
|Topic ID||Project Title||Curriculum||Pre-clinical Supervisor||Clinical Supervisor||Laboratory Name||Clinical Unit Name|
|MEM 1||CDK4/6i toxicity profiling and potential prophylactic ¬application of a microbiota-stabilizer on gastrointestinal toxicity||Clinical||Prof. Maria Rescigno||Prof. Armando Santoro||Mucosal immunology and microbiota Unit||Medical Oncology and Hematology Unit|
|MEM 3||A humanized model of blood brain barrier to investigate immune cells infiltration in multiple sclerosis: toward a personalized medicine approach||Standard||Prof. Michela Matteoli||–||Pharmacology and Brain Pathology Lab||–|
|MEM 4||Immune-synaptopathies: dissecting the contribution of inflammation to synaptic dysfunctions||Standard||Prof. Michela Matteoli||–||Pharmacology and Brain Pathology Lab||–|
|MEM 5||The role of Histology in IBD||Clinical||Prof. Silvio Danese||Prof. Silvio Danese||IBD center, Department of Gastroenterology||IBD center, Department of Gastroenterology|
|MEM 6||Anti-inflammatory role of oxytocin in 22q11.2 deletion syndrome: cellular and molecular signaling mechanisms in the developing brain||Standard||Dr. Bice Chini and Prof. Michela Matteoli||–||Neurobiology of oxytocin and vasopressin receptors Lab||–|
|MEM 8||Immune and genetic mechanisms of heart failure||Clinical||Prof. Gianluigi Condorelli||Prof. Gianluigi Condorelli||Molecular Cardiology Lab||Department of Cardiovascular Medicine|
|MEM 9||Genetic and epigenetic identities of cardiovascular diseases||Standard||Prof. Gianluigi Condorelli||–||Molecular Cardiology Lab||–|
|MEM 10||Efficacy analysis and development of new therapeutic strategies with oxygen-ozone therapy for the treatment of musculoskeletal degenerative diseases||Clinical||Prof. Elizaveta Kon||Dr. Stefano Respizzi||Department of Orthopedy||Department of Rehabilitation and Functional Recovery|
|MEM 11||Cancer-associated fibroblasts role and PET/CT imaging in refractory and relapsed Hodgkin disease||Clinical||Prof. Carmelo Carlo-Stella||Prof. Arturo Chiti||Cancer Experimental Therapeutics Lab||Department of Diagnostic Imaging|
|MEM 12||Application of high-dimensional technologies to profile the immune composition in cancer||Standard||Dr. Diletta Di Mitri||–||Tumor microenvironment Unit||–|
|MEM 13||Cellular immune responses against human cancer||Standard||Dr. Enrico Lugli||–||Translational Immunology Lab||–|
|MEM 14||Decoding the immune heterogeneity of intrahepatic cholangiocarcinoma||Standard||Dr. Enrico Lugli||Prof. Ana Lleo||Hepatobiliary Immunopathology Lab||–|
|MEM 15||Role of DNA methylation in cardiovascular diseases||Standard||Prof. Gianluigi Condorelli||–||Inflammation and Immunology in Cardiovascular Pathologies Lab||–|
|MEM 16||Disease specific universal vaccines as new combinatorial immunotherapy for metastatic melanoma sarcoma and osteosarcoma||Standard||Prof. Maria Rescigno||–||Mucosal immunology and microbiota Unit||–|
|MEM 17||The role of innate immunity in tumor immunoediting and in response to cancer immunotherapies||Standard||Dr. Sebastien Jaillon||–||Laboratory of experimental immunopathology|